Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Previous research evaluating the use of adjuvant endocrine therapy among postmenopausal breast cancer patients showed with 15-50% wide ranges of non-adherence rates. We evaluated this issue by analysing an unselected study group comprising of 325 postmenopausal women, diagnosed from 1997 to 2003 with hormonal receptor-positive invasive breast cancer. The different clinical situations that led to the discontinuation of adjuvant endocrine therapy were clearly defined and differentiated: non-adherence was not simply the act of stopping medication, but rather the manifestation of an intentional behaviour of the patient. Of the 287 patients who initiated endocrine therapy, 191 (66.6%) fully completed this treatment. Thirty-one patients (10.8%) showed non-adherence to therapy. Patients who had follow-up with a general practitioner, rather than in an oncologic unit, were more likely to be non-adherent (P=0.0088). Of 25 patients who changed medication due to therapy-related adverse effects, 20 (80%) patients fully completed the therapy after drug change. In adjuvant endocrine therapy, a lowering of the non-adherence rate to 10.8%, the lowest reported in the literature, is realistic when patients are cared for by a specialised oncologic unit focusing on the individual needs of the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676 · cited 9×
“Most clinical practise studies only analysed a predominantly geriatric study group (Silliman et al, 2002; Partridge et al, 2003; Fink et al, 2004; Lash et al, 2006; Barron et al, 2007; Owusu et al, 2008).”
BackgroundMethodInfluentialIntentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251 · cited 4×
“Several studies performed in a clinical practise setting demonstrated that adherence to endocrine therapy was influenced by certain factors such as age, adverse effects, patient beliefs about the risks and benefits of tamoxifen use, history of medication and good patient –doctor relationship (Chlebowski and Geller, 20…”
BackgroundResultInfluential
Cited by
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
“, there was no distinction between treatment with tamoxifen and treatment with aromatase inhibitors), discontinuation rates ranged from 32 to 73 % at the end of 5 years of treatment [11, 26, 40, 41, 46].”
Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., & Van Hecke, A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.014 · Cited by 202
Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr330 · Cited by 133
Huiart, L., Ferdynus, C., & Giorgi, R. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2422-4 · Cited by 106
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Wouters, H., Stiggelbout, A. M., Bouvy, M. L., Maatman, G. A., Van Geffen, E. C. G., Vree, R., Nortier, J. W., & Van Dijk, L. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.04.005 · Cited by 46
Metadata
- Authors
- Güth, U., Huang, D. J., Schötzau, A., Zanetti-Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E.
- Venue
- British Journal of Cancer
- Published
- 2008-07-29
- Volume
- 99
- Issue
- 3
- Pages
- 428-433
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2116157738
- Cited by
- 56
- References
- 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.